WO2012142615A3 - Auranofin and auranofin analogs useful to treat proliferative disease and disorders - Google Patents

Auranofin and auranofin analogs useful to treat proliferative disease and disorders Download PDF

Info

Publication number
WO2012142615A3
WO2012142615A3 PCT/US2012/033837 US2012033837W WO2012142615A3 WO 2012142615 A3 WO2012142615 A3 WO 2012142615A3 US 2012033837 W US2012033837 W US 2012033837W WO 2012142615 A3 WO2012142615 A3 WO 2012142615A3
Authority
WO
WIPO (PCT)
Prior art keywords
auranofin
disorders
treat proliferative
proliferative disease
compounds
Prior art date
Application number
PCT/US2012/033837
Other languages
French (fr)
Other versions
WO2012142615A2 (en
Inventor
Waldemar Priebe
Takayuki Kato
Izabela Fokt
Charles Conrad
Timothy Madden
Stanislaw Skora
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Publication of WO2012142615A2 publication Critical patent/WO2012142615A2/en
Publication of WO2012142615A3 publication Critical patent/WO2012142615A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Auranofin analogs and pharmaceutical compositions which inhibit p-STAT3 are provided together methods of synthesizing and methods of using the compounds. Also provided are methods of treating p-STAT3 diseases and disorders in a patient in need thereof by administering a therapeutically effective amount of one or more of these compounds, alone or in combination with another drug therapy. The compounds and pharmaceutical compositions disclosed are useful to treat proliferative diseases and disorders including, but not limited to, cancer.
PCT/US2012/033837 2011-04-14 2012-04-16 Auranofin and auranofin analogs useful to treat proliferative disease and disorders WO2012142615A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161475600P 2011-04-14 2011-04-14
US61/475,600 2011-04-14

Publications (2)

Publication Number Publication Date
WO2012142615A2 WO2012142615A2 (en) 2012-10-18
WO2012142615A3 true WO2012142615A3 (en) 2013-01-31

Family

ID=47010040

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/033837 WO2012142615A2 (en) 2011-04-14 2012-04-16 Auranofin and auranofin analogs useful to treat proliferative disease and disorders

Country Status (1)

Country Link
WO (1) WO2012142615A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010005799A2 (en) 2008-07-11 2010-01-14 Board Of Regents, The University Of Texas System Novel acetates of 2-deoxy monosaccharides with anticancer activity
HUE056881T2 (en) 2013-04-05 2022-03-28 Univ Texas Esters of 2-deoxy-monosaccharides with anti proliferative activity
WO2015127234A1 (en) * 2014-02-20 2015-08-27 Board Of Regents, The University Of Texas System Use of ibrutinib to treat egfr mutant cancer
CN103980330B (en) * 2014-04-04 2017-02-01 济南圣泉唐和唐生物科技有限公司 Preparation method of isothiourea dihydrobromide
CN107043404B (en) * 2016-11-24 2020-08-11 中山大学肿瘤防治中心 Novel phosphine gold complex and anti-tumor application thereof
TW202106676A (en) 2019-04-05 2021-02-16 美商凱麥拉醫療公司 Stat degraders and uses thereof
CN112206238A (en) * 2019-07-09 2021-01-12 厦门大学 Application of auranofin in lung cancer treatment
AT523662B1 (en) 2020-03-16 2023-07-15 Aurovir Pharma Gmbh Gold-containing medicines used to treat lung infections
WO2023242100A1 (en) 2022-06-13 2023-12-21 KHR Biotec GmbH Novel ras inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018598A2 (en) * 2001-08-30 2003-03-06 University College Dublin Monosaccharide derivatives
US20050043250A1 (en) * 2000-05-01 2005-02-24 Lampidis Theodore J. Cancer treatment including glycolytic inhibitors
US20050143336A1 (en) * 2003-12-30 2005-06-30 Board Of Regents, The University Of Texas System Methods and compositions for improved non-viral gene therapy
WO2010005799A2 (en) * 2008-07-11 2010-01-14 Board Of Regents, The University Of Texas System Novel acetates of 2-deoxy monosaccharides with anticancer activity
US20100130434A1 (en) * 2006-02-24 2010-05-27 Board Of Regents, The University Of Texas System Hexose Compounds to Treat Cancer
US20110003758A1 (en) * 2006-04-27 2011-01-06 Waldemar Priebe Inhibitors of Glycolysis Useful In the Treatment of Brain Tumors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043250A1 (en) * 2000-05-01 2005-02-24 Lampidis Theodore J. Cancer treatment including glycolytic inhibitors
WO2003018598A2 (en) * 2001-08-30 2003-03-06 University College Dublin Monosaccharide derivatives
US20050143336A1 (en) * 2003-12-30 2005-06-30 Board Of Regents, The University Of Texas System Methods and compositions for improved non-viral gene therapy
US20100130434A1 (en) * 2006-02-24 2010-05-27 Board Of Regents, The University Of Texas System Hexose Compounds to Treat Cancer
US20110003758A1 (en) * 2006-04-27 2011-01-06 Waldemar Priebe Inhibitors of Glycolysis Useful In the Treatment of Brain Tumors
WO2010005799A2 (en) * 2008-07-11 2010-01-14 Board Of Regents, The University Of Texas System Novel acetates of 2-deoxy monosaccharides with anticancer activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIM, N. H. ET AL.: "Auranofin blocks interleukin-6 signalling by inhibiting p hosphorylation of JAK1 and STAT3.", IMMUNOLOGY., vol. 122, no. 4, 2007, pages 6 07 - 614, XP055237295, DOI: doi:10.1111/j.1365-2567.2007.02679.x *

Also Published As

Publication number Publication date
WO2012142615A2 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
WO2012142615A3 (en) Auranofin and auranofin analogs useful to treat proliferative disease and disorders
WO2013188847A8 (en) Compositions and methods for transmucosal absorption
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
MX2010005631A (en) Novel cyclic hydrocarbon compounds for the treatment of diseases.
IN2012DN06720A (en)
EA201500365A1 (en) COMBINATION OF REGORAPHENIBE AND ACETYLSALICYLIC ACID TO CURE CANCER
IN2015DN00376A (en)
MX2014002171A (en) Combination treatments for hepatitis c.
BR112015010396A2 (en) combination therapy
MX2013012588A (en) Kinase inhibitors.
EA201171088A1 (en) TREATMENT OF DISKINESIA IN DIFFERENT DISORDERS
WO2016090024A3 (en) Combination therapy for treatment of cancer
WO2012116176A3 (en) Asymmetric ureas and medical uses thereof
WO2014078575A3 (en) Novel orally bioavailable breathing control modulating compounds, and methods of using same
WO2013085849A3 (en) Sulfate esters of noribogaine
WO2015009731A3 (en) Azacyclic constrained analogs of fty720
WO2014100679A8 (en) Stimulation and enhancement of regeneration of tissues
WO2013173096A3 (en) Conjugates of huperzine and analogs thereof
BR112015007095A2 (en) dihydro-6-azafenalene derivatives for the treatment of snc, cancer and related disorders
MX2014011843A (en) Compounds for use in the treatment of neuroblastoma, ewing's sarcoma or rhabdomyosarcoma.
MX368641B (en) Compounds for treating inflammation and pain.
WO2013181217A3 (en) Novel compounds and compositions for treatment of breathing control disorders or diseases
TW201613599A (en) Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease
MX2014000870A (en) Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2- ylidene)-1h-benzimidazol-5-amine for treating retinal diseases.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12771343

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12771343

Country of ref document: EP

Kind code of ref document: A2